Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05344638
Other study ID # AG1904
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date October 17, 2019
Est. completion date July 29, 2020

Study information

Verified date April 2022
Source Ahn-Gook Pharmaceuticals Co.,Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Multicenter, Randomized, Double-Blind, Parallel, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of AGS Compared to AGU for Acute Bronchitis


Recruitment information / eligibility

Status Completed
Enrollment 220
Est. completion date July 29, 2020
Est. primary completion date July 29, 2020
Accepts healthy volunteers No
Gender All
Age group 19 Years to 75 Years
Eligibility Inclusion Criteria: - Both gender, 19 years = age = 75 years - BSS(Bronchitis Severity Score) = 5point at Visit 2 (Randomized Visit) - Patients without fever based on Visit 2(Randomized Visit) - Those who can comply with the requirements of clinical trials - Written consent voluntarily to participate in this clinical trial Exclusion Criteria: - Patients with respiratory and systemic infections requiring systemic antibiotic therapy - Patients with bleeding tendency or coagulation disorder - Patients who investigators determines to severe respiratory disease that would interfere with study assessment - Those who have participated in other clinical trials within 4 weeks before participating in clinical trials - In case the investigator judges that it is not suitable for the subject of this clinical trial for other reasons

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AGS (Experimental)
tid
AGU (Active Comparator)
tid

Locations

Country Name City State
Korea, Republic of Konkuk University Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Ahn-Gook Pharmaceuticals Co.,Ltd

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bronchitis Severity Total Score(BSS) change of Visit 3 compared to Visit 2 The BSS comprises the following five symptoms typical for Acute Bronchitis: cough, sputum, rales/rhonchi on auscultation, chest pain during coughing, and dyspnea. These symptoms are each assessed according to a 5-point scale: 0 = absent, 1 = mild, 2 = moderate, 3 = severe and 4 = very severe Visit 1 (-3 day), Visit 2 (0 day), Visit 3 (7 day)
Secondary Individual symptom score of Bronchitis Severity Score(BSS) of Visit 3 compared to Visit 2 7days
Secondary Treatment response rate at Visit 3 7days
Secondary Integrative Medicine Outcome Scale (IMOS) 7days
Secondary Integrative Medicine Patient Satisfaction Scale (IMPSS) 7days
See also
  Status Clinical Trial Phase
Completed NCT03711292 - Using Behavioral Science to Reduce Inappropriate Antibiotic Use in Acute Care Settings N/A
Not yet recruiting NCT03517215 - The Development and Testing of a Scaling Strategy for a Community-Based Primary Care Antimicrobial Stewardship Program N/A
Completed NCT01420445 - Safety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic Bronchitis Phase 2
Completed NCT00360464 - A Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases Phase 3
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Recruiting NCT03827590 - Clinical Trials to Assess the Efficacy and Safety of HLIM Phase 3
Completed NCT02792946 - Compare the Efficacy and Safety of Surfolase CR Tablet With Surfolase Capsule in Patients With Acute Bronchitis Phase 3
Completed NCT01875757 - Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life Phase 3
Recruiting NCT04252963 - Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase) Phase 4
Recruiting NCT06411925 - The Efficacy and Safety of Atock Dry Syrup With Acute Bronchitis Patients Phase 4
Completed NCT01416480 - Clinical Trial to Evaluate the Safety and Efficacy of "Theobromine Capsule" as an Antitussive in Acute Cougher Phase 3
Enrolling by invitation NCT05916768 - Management of Acute Bronchitis With Pelargonium Sidoides Extract N/A
Completed NCT03309800 - A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Placebo in Acute Bronchitis Patients Phase 2
Completed NCT02250027 - A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on) Phase 2
Not yet recruiting NCT03310385 - Efficacy and Safety of GHX02 in the Treatment of Acute Bronchitis Phase 2
Completed NCT03654196 - A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Umkamin Tab in Acute Bronchitis Patients Phase 3
Completed NCT03011515 - Evaluating a Host-response Based Diagnostic for Distinguishing Between Bacterial and Viral Etiology in Patients With Lower Respiratory Tract Infection (LRTI)
Completed NCT02045394 - Epidemiology and Diagnosis of Haemoptysis: a Multicenter Study N/A
Completed NCT01800747 - Clinical Trial for the Assessment of Delayed Antibiotic Treatment in Pediatric (DAP-Pediatrics) Phase 4
Recruiting NCT06142994 - Treatment of Adults With Acute Bronchitis in the Primary Healthcare Setting N/A